225Ac-J591,lutetium-177 psma-i&t,68Ga-PSMA-11
Alkido pharma,Point Biopharma,Novartis,ARTMS,Telix Pharmaceuticals
['crpc', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', '225ac']
tip: ph i/ii dose-esc study of fractionated 225ac-j591 for progressive mcrpc in pts with prior 177lu-psma #gu23 rx: will be given in a single fractionated cycle of 225ac-j591 administered on d1 and d15 ph 1: 3+3 dose-escalation; ph 2: 16-19 pts 
Uro Onc @GACancerCenter | Res PD & Ronald W. Lewis MD Chair of Uro Educ @mcg_urology | Digital Media Ed @EUplatinum | #mentalhealth research | @urotoday